U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07591181) titled 'A Study on the Immunization Schedule for the 13-Valent Pneumococcal Polysaccharide-Conjugate Vaccine in Healthy Infants' on May 09.
Brief Summary: To compare the immunogenicity of the domestically produced PCV13 vaccine in healthy 2-month-old infants following administration via the 2+1 and 3+1 schedules, with the primary endpoint being the seroprevalence of specific IgG antibodies after completion of the vaccination series.To evaluate the safety of the 2+1 schedule in infants and young children (incidence of adverse events and serious adverse events).
Study Start Date: May 10
Study Type: INTERVENTIONAL
Condition:
Pneumococcal Di...